Creative Medical Technology Holdings, Inc. Files 10-Q for Q1 2024

TL;DR

<b>Creative Medical Technology Holdings, Inc. filed its Q1 2024 10-Q, detailing financial activities and intellectual property.</b>

AI Summary

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. The company filed a 10-Q for the period ending March 31, 2024. The filing includes data related to various agreements and patents, including the JadiCell License Agreement and StemSpine Patent Purchase. Information on stock options and warrants is detailed for the period. The company's fiscal year ends on December 31. The filing references specific dates for various corporate actions and agreements.

Why It Matters

For investors and stakeholders tracking CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., this filing contains several important signals. This 10-Q provides a quarterly update on the company's financial health and operational progress, crucial for investors to assess performance. The detailed information on patents and agreements offers insight into the company's intellectual property strategy and potential future revenue streams.

Risk Assessment

Risk Level: low — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial and operational updates without immediate indicators of significant new risks or opportunities.

Analyst Insight

Review the detailed financial statements and disclosures within the 10-Q to understand the company's current financial position and operational developments.

Key Numbers

• 2024-03-31 — Period End Date (Conformed period of report)
• 2024-05-10 — Filing Date (Filed as of date)
• 2024-01-01 — Q1 Start Date (Reporting period start date)
• 1231 — Fiscal Year End (Fiscal year end date)

Key Players & Entities

• CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (company) — Filer name
• CELZ (company) — Ticker symbol
• 2024-03-31 (date) — Period of report
• 2024-05-10 (date) — Filed as of date
• 2024-01-01 (date) — Start of Q1 2024
• JOLLEY MARKETING INC (company) — Former company name
• NV (jurisdiction) — State of incorporation
• 1934 Act (regulation) — SEC Act

FAQ

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-10: Filing Date — Date the 10-Q was officially filed with the SEC.
• 2024-01-01: Quarterly Period Start — Beginning of the first quarter of 2024.
• 1231: Fiscal Year End — Indicates the company's annual reporting cycle.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides investors with a timely update on the company's financial condition and operational performance.)

JadiCell License Agreement

A specific licensing agreement related to the company's technology. (Indicates a potential revenue stream or partnership for the company's core technology.)

StemSpine Patent Purchase

An agreement for the acquisition of patents related to StemSpine technology. (Highlights the company's investment in and ownership of intellectual property critical for its business.)

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CELZ The NASDAQ Stock Mar
• $0.01 — ny's shares of common stock trade below $0.01 per share for two or more consecutive t
• $300,000 — mon stock. The remaining portion of the $300,000 obligation was paid in cash in 2020. In

Filing Documents

• celz_10q.htm (10-Q) — 441KB
• celz_ex311.htm (EX-31.1) — 10KB
• celz_ex312.htm (EX-31.2) — 10KB
• celz_ex321.htm (EX-32.1) — 4KB
• celz_ex322.htm (EX-32.2) — 4KB
• celz_10qimg1.jpg (GRAPHIC) — 28KB
• 0001477932-24-002695.txt (&nbsp;) — 2562KB
• celz-20240331.xsd (EX-101.SCH) — 27KB
• celz-20240331_lab.xml (EX-101.LAB) — 178KB
• celz-20240331_cal.xml (EX-101.CAL) — 28KB
• celz-20240331_pre.xml (EX-101.PRE) — 148KB
• celz-20240331_def.xml (EX-101.DEF) — 81KB
• celz_10q_htm.xml (XML) — 258KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets 3 Unaudited Condensed Consolidated Statements of Operations 4 Unaudited Condensed Consolidated Statements of Cash Flows 5 Unaudited Condensed Consolidated Statements of Stockholder' Equity (Deficit) 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 20 Item 6. Exhibits 21 2 Table of Contents CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2024 December 31, 2023 ASSETS CURRENT ASSETS Cash $ 9,007,398 $ 3,466,867 Investments - 6,520,191 Inventory 6,594 6,594 Prepaids and other current assets 190,564 277,246 Total Current Assets 9,204,556 10,270,898 OTHER ASSETS Other assets 3,281 3,281 Licenses, net of amortization 411,740 441,011 TOTAL ASSETS $ 9,619,577 $ 10,715,190 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable $ 336,845 $ 317,280 Accrued expenses 39,920 39,920 Advances from related party 14,194 14,194 Total Current Liabilities 390,959 371,394 TOTAL LIABILITIES 390,959 371,394 STOCKHOLDERS' EQUITY Common stock, $ 0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,126 and 1,431,126 issued and 1,354,626 and 1,373,626 outstanding at March 31, 2024 and December 31, 2023, respectively 1,431 1,431 Additional paid-in capital 69,720,911 69,711,749 Accumulated deficit ( 60,139,976 ) ( 59,098,432 ) Treasury stock, at cost, 76,500 and 57,500 shares as of March 31, 2024 and December 31, 2023 ( 353,748 ) ( 270,952 ) TOTAL STOCKHOLDERS' EQUITY 9,228,618 10,343,796 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 9,619,577 $ 10,715,190 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three Months Ended March 31, 2024 For the Three Months Ended March 31, 2023 Revenues $ - $ - Cost of revenues - - Gross profit - - OPERATING EXPENSES Research and development 422,392 319,029 Se

View Full Filing

View this 10-Q filing on SEC EDGAR